| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 14, 2009
Revised on September 30, 2009
Accepted on September 30, 2009
From the Department of Cardiothoracic Surgery (D.A.D., R.B., M.O.Z., D.S., R.E.M.), Montefiore Medical Center, Albert Einstein College of Medicine, New York; Departments of Anesthesia and Medicine and Cardiovascular Division (J.K., T.H., A.G., F.M., S.B., H.Z., D.D., M.E.P.-I., A.B.C., M.R., K.U., A.L., P.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, Mass; and Medical Research Council Clinical Sciences Centre (F.M., O.R.), Faculty of Medicine, Imperial College School of Medicine, London, United Kingdom.
* To whom correspondence should be addressed. E-mail: panversa{at}partners.org.
Rationale: Chronic rejection, accelerated coronary atherosclerosis, myocardial infarction, and ischemic heart failure determine the unfavorable evolution of the transplanted heart in humans.
Objective: Here we tested whether the pathological manifestations of the transplanted heart can be corrected partly by a strategy that implements the use of cardiac progenitor cells from the recipient to repopulate the donor heart with immunocompatible cardiomyocytes and coronary vessels.
Methods and Results: A large number of cardiomyocytes and coronary vessels were created in a rather short period of time from the delivery, engraftment, and differentiation of cardiac progenitor cells from the recipient. A proportion of newly formed cardiomyocytes acquired adult characteristics and was integrated structurally and functionally within the transplant. Similarly, the regenerated arteries, arterioles, and capillaries were operative and contributed to the oxygenation of the chimeric myocardium. Attenuation in the extent of acute damage by repopulating cardiomyocytes and vessels decreased significantly the magnitude of myocardial scarring preserving partly the integrity of the donor heart.
Conclusions: Our data suggest that tissue regeneration by differentiation of recipient cardiac progenitor cells restored a significant portion of the rejected donor myocardium. Ultimately, immunosuppressive therapy may be only partially required improving quality of life and lifespan of patients with cardiac transplantation.
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2009 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |